Stockscreener 앱 받기
1.80
1.64%
-0.03
시간 외 거래:
1.86
0.06
+3.33%
전일 마감가:
$1.83
열려 있는:
$1.89
하루 거래량:
334.13K
Relative Volume:
0.95
시가총액:
$44.48M
수익:
-
순이익/손실:
$-16.51M
주가수익비율:
-1.3306
EPS:
-1.3528
순현금흐름:
$-15.68M
1주 성능:
-16.67%
1개월 성능:
-18.18%
6개월 성능:
-32.33%
1년 성능:
-38.98%
1일 변동 폭
$1.77
$1.9399
1주일 범위
$1.77
$2.18
52주 변동 폭
$1.675
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
명칭
Medicus Pharma Ltd
전화
610-540-7515
주소
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
MDCX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
1.80 | 45.22M | 0 | -16.51M | -15.68M | -1.3528 |
|
LLY
Lilly Eli Co
|
1,054.29 | 950.68B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
209.30 | 516.00B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.67 | 401.99B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
135.03 | 259.40B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
98.27 | 248.85B | 63.90B | 19.05B | 13.05B | 7.5596 |
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Medicus Pharma completes patient enrollment for phase 2 BCC treatment study - MSN
Medicus Pharma completes enrollment in Phase 2 skin cancer microneedle study - Proactive financial news
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Columbia Daily Tribune
Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK - TMX Newsfile
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC - Dermatology Times
Small cap wrap: EnWave, Medicus Pharma, Ocean Power Technologies, EDM Resources, C3 Metals… - Proactive financial news
Medicus Pharma completes enrollment for Phase 2 basal cell carcinoma study - Proactive financial news
Medicus Pharma Completes Patient Enrollment for Phase 2 BCC Treatment Study - TipRanks
Medicus Pharma (MDCX) Analyst Rating Maintained by D. Boral Capi - GuruFocus
Medicus Pharma completes enrollment of 90 patients for Phase 2 study - TipRanks
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - The Manila Times
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) - GlobeNewswire
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - Greenville Online
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025 - Victorville Daily Press
Medicus Pharma’s Warrant Inducement Agreement Announced - TipRanks
Medicus Pharma Elevates President Carolyn Bonner to CFO as Clinical Pipeline Accelerates - MyChesCo
Medicus Pharma Ltd. To Present at Brookline Capital Markets - Daytona Beach News-Journal
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE - Daytona Beach News-Journal
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - The Asheville Citizen Times
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing - The Times Telegram
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject - Daytona Beach News-Journal
Medicus Pharma secures $5.1 million from warrant exercise agreement By Investing.com - Investing.com Nigeria
Medicus Pharma secures $5.1 million from warrant exercise agreement - Investing.com India
Medicus Pharma Ltd (MDCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
0.44%
자본화:
|
볼륨(24시간):